Nextrials Presents to FDA on the Viability of Integrating Electronic Health Records for Improved Clinical Data and Drug Safety Reporting
SAN RAMON, CA and WASHINGTON, DC--(Marketwired - Jun 15, 2015) - (DIA 2015) -- At the invitation of the Food and Drug Administration (FDA),
This demonstration enabled attendees to examine how the integration of electronic data collection (EDC) in clinical trials with individual patient EHRs could not only provide benefits from a regulatory perspective, but also could boost patient care from the standpoint of healthcare providers.
"We have worked alongside the FDA in the past on the related standards and also collaborated with them on live demos of the integration," said Nextrials CEO James Rogers. "This recent forum allowed us to engage in a productive discussion of how patient data collected directly from his or her EHR record can improve data quality and streamline drug safety reporting."
Nextrials also met with authors of the FDA eSource Guidance. The eSource Guidance provides recommendations for the use of electronic source data in FDA-regulated clinical investigations. The application of this guidance was discussed from the perspective of sponsors, patients, e-clinical software vendors and treating physicians.
Attendees at the
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025
- IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025
- Managing Background Therapies in the NIMBLE Phase III Trial
September 17th 2025
- Generative AI Transforms Clinical Study Report Development
September 16th 2025